Skip to content


Open Access

Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet

  • J Lubiński1Email author,
  • T Huzarski1,
  • A Jakubowska1,
  • J Gronwald1,
  • K Jaworska1,
  • M Muszyńska1,
  • G Sukiennicki1,
  • K Durda1,
  • C Cybulski1,
  • T Dębniak1,
  • A Tołoczko1,
  • O Oszurek1,
  • P Serrano-Fernandez1,
  • R Scott1 and
  • S Narod1
Hereditary Cancer in Clinical Practice201210(Suppl 1):A11

Published: 12 January 2012


Public HealthSeleniumCancer ResearchCancer RiskFood Product

The aim of the study is to observe prospectively the possibility of lowering the cancer risk among BRCA1 carriers by optimizing selenium concentration in diet/organism. Results of studies performed in several centres, particularly of our own search, are strongly indicating on potential of decreasing breast/ovarian cancer risk among carriers by optimization of selenium concentration in the body. Studies will be performed on group of 1500 BRCA1 carriers. Cohort will be recruited during the first 6 months of the project. Mean length of follow-up will be 3 yrs. From all females serum will be collected for selenium analyses-at the beginning and, then, every 6 months. Participants will receive the list of products with selenium concentration estimated according to literature data and, additionally, information about e-store ( specialized in distribution of food products with defined amount of selenium. Information on optimal selenium concentration according to existing data will be provided also. It is expected that among ~750 carriers following recommended diet changes 38 cancers will be diagnosed and among the others ~750-60. The difference between groups will be statistically significant with p=0.0278. If necessary, investigation will be extended.

Authors’ Affiliations

International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland


© Lubińński et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.